Transplant and Cellular Therapy

Autologous Stem Cell Transplant for Multiple Myeloma in India

A detailed international-patient guide to preparing for specialist review, comparing the proposed approach and coordinating the journey around the confirmed clinical plan.

Request specialist review View cost planning →

HSCT and BMT safeguard

Haematopoietic stem-cell transplantation requires specialist programme review.

Autologous and allogeneic HSCT are distinct from solid-organ transplantation. Organ-allocation and deceased-donor waiting-list language does not apply to these pages.

Use an appropriate haematology transplant programme

The treating programme must confirm the indication, patient fitness, cell source, conditioning plan, laboratory and infection-control pathway, consent and follow-up requirements.

For allogeneic HSCT, donor suitability requires independent medical assessment, HLA and compatibility work-up, infection screening, voluntary informed consent and a safe collection plan.
For autologous HSCT, the patient’s own cells are mobilised, collected, processed, stored and reinfused; donor relationship and organ-allocation processes are not relevant.
Cell identity, collection, processing, storage, transport, traceability and release should follow the treating programme’s quality and safety procedures.
Established HSCT for recognised indications must not be confused with unproven “stem-cell therapy.” Investigational use requires the applicable ethics, clinical-trial and regulatory review.
Cell or stem-cell-derived products that fall within India’s new-drug framework may require CDSCO permissions under the New Drugs and Clinical Trials Rules; the treating institution must determine what applies to the proposed product or protocol.
No enquiry, estimate or travel arrangement confirms candidacy, donor suitability, engraftment or outcome.

ICMR National Guidelines for Hematopoietic Cell Transplantation ↗CDSCO New Drugs and Clinical Trials framework ↗

Procedure overview

Start with diagnosis and purpose.

Autologous stem-cell transplantation for multiple myeloma collects the patient’s own blood-forming cells, gives high-dose therapy and then returns the stored cells to restore marrow function. It is commonly part of a broader myeloma plan rather than a stand-alone cure.

Autologous Stem Cell Transplant for Multiple Myeloma is a named clinical pathway, but the name alone does not define the exact treatment. Technique, complexity, expected benefit and recovery depend on the individual findings and the hospital team’s assessment.

A useful preliminary review should clarify what diagnosis is established, why this procedure is being considered, whether further tests are needed, what alternatives exist and which parts of the plan remain provisional until examination.

No outcome can be guaranteed.

Ask the treating clinician to explain patient-specific benefits, material risks, uncertainty and what may happen without treatment.

Possible indications

When a specialist may consider it

Confirmed multiple myeloma with a treatment plan that includes high-dose therapy
Adequate response or disease control before collection and transplant
Heart, lung, liver and kidney function sufficient for conditioning
Performance status and support plan compatible with intensive treatment

Clinical assessment

Evaluation before a recommendation

Myeloma subtype, stage, cytogenetics, treatment response and previous medicines
Bone-marrow, blood, urine and imaging assessment as clinically indicated
Stem-cell mobilisation and collection feasibility
Infection screening, organ tests, fertility and supportive-care planning

Treatment options

Approaches the team may compare

Stem-cell mobilisation and collection followed by high-dose conditioning and reinfusion
Single or selected tandem autologous transplant strategies
Non-transplant systemic treatment when risk, response or preference favours another pathway

Informed consent

Important risks to discuss

Severe infection, bleeding and anaemia while blood counts are low
Mouth and digestive-tract inflammation, nausea, fatigue and nutritional difficulty
Organ toxicity, infertility and possible later secondary cancers related to conditioning treatment
Delayed engraftment or relapse; allogeneic transplant also carries graft-versus-host disease and graft rejection risk

This is not a complete risk list. Personal risk can only be explained by the treating clinician after assessment.

Information for review

Records the hospital may request

Current diagnosis, symptom timeline and specialist notes
Relevant laboratory, imaging, pathology or functional-test reports
Original image files or pathology material when requested
Previous operations, procedures and treatment response
Current medicines, allergies and important medical conditions

Questions to compare

What the specialist should clarify

What is the goal of Autologous Stem Cell Transplant for Multiple Myeloma in this case?
What non-procedural or alternative procedural options are reasonable?
Which technique, device, implant or technology is proposed and why?
What are the important risks and possible need for additional treatment?
What recovery, rehabilitation and long-term follow-up are expected?

International patient pathway

From record review to safe return.

Clinical confirmation should lead the travel plan—not the other way around.

01
Case preparation
Organize the diagnosis, medical timeline, reports and questions.
02
Hospital review
Coordinate an appropriate department and preliminary opinion.
03
Estimate and schedule
Request a written institutional estimate and expected stay.
04
Treatment and discharge
Collect the confirmed plan, records, prescriptions and warning signs.
05
Return and follow-up
Travel only after fitness advice and continue care at home.

Recovery planning

Before booking a return flight

Conditioning, cell infusion, engraftment and early monitoring form one continuous treatment pathway
Blood counts, infection signs and organ function are checked frequently
Immune recovery takes months and is generally longer after an allogeneic transplant
Travel, vaccination, food-safety and home-monitoring instructions must be agreed before departure

Financial planning

Autologous Stem Cell Transplant for Multiple Myeloma cost in India

A current estimate depends on the exact clinical scope, hospital, treating team, devices or medicines, room category and expected stay.

Open cost-planning guide

Relevant doctors

Specialists related to Autologous Stem Cell Transplant for Multiple Myeloma

Explore specialists whose published clinical focus relates to this treatment. Final selection depends on medical-record review, current hospital association and appointment availability.

Search all doctors →